Go to the list of all blogs
Anna G's Avatar
published in Blogs
Dec 04, 2023
$CAH, $MCK, $HSIC, $OMI, $PDCO Spearhead +5.61% Monthly Uptick in Medical Distributors

$CAH, $MCK, $HSIC, $OMI, $PDCO Spearhead +5.61% Monthly Uptick in Medical Distributors

AI Trading Made Easy for Beginners: Swing Trading Strategies in the Medical Distributors Sector! Venture into trading with confidence using these beginner-friendly AI swing trading strategies, specifically tailored for the Medical Distributors sector:   Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA) - Perfect for newcomers, this strategy is crafted for markets on an upward trajectory. It combines technical and fundamental analysis to uncover potential trading opportunities in the ascending Medical Distributors sector and Swing Trader for Beginners: Search for Trend Reversals (TA&FA) - Also designed for beginners, this strategy focuses on identifying trend reversals. It employs both technical and fundamental analysis to pinpoint potential shifts in the Medical Distributors sector, guiding you to spot turning points in the market.  Both strategies are geared towards easing beginners into the realm of trading decisions​​​​​​​

Medical Distributors: Navigating a Healthy 5.61% Monthly Gain in the Market

In this blog, we delve into the robust growth of the Medical Distributors sector, which has witnessed a notable 5.61% increase over the past month. We'll explore the performance and prospects of leading companies like $CAH, $MCK, and $HSIC, shedding light on their contributions to this sector's positive outlook.


In-Depth Ticker Analysis

  1. $CAH (Cardinal Health, Inc.)

    • Uptrend Indicator: The stock's upward movement suggests potential growth.
    • Market Outlook: With a high likelihood of continued growth, $CAH is a significant player in the sector.
  2. $MCK (McKesson Corporation)

    • Trend Analysis: A consistent uptrend indicates a strong market position.
    • Investment Potential: $MCK's current performance and growth trajectory make it an attractive investment option.
  3. $HSIC (Henry Schein, Inc.)

    • RSI Indicator: Recovery from oversold territory suggests potential for upward trend.
    • Stock Forecast: Given its recovery and positive indicators, $HSIC might be a stock to watch.
  4. $OMI (Owens & Minor, Inc.)

    • Momentum Indicator: Positive shift indicates new growth potential.
    • Trading Strategy: $OMI's recent performance suggests it could be a strategic choice for potential investors.
  5. $PDCO (Patterson Companies, Inc.)

    • Stochastic Oscillator: Watch for a potential price bounce soon.
    • Market Position: Despite recent downtrends, $PDCO presents a dynamic scenario in the sector.

🚑 Medical Distributors Sector Overview

The Medical Distributors sector, comprising companies involved in the distribution of pharmaceutical and medical products, plays a crucial role in the healthcare supply chain. This sector includes pharmaceutical product distribution, medical device distribution, and biopharmaceutical product distribution services.

📈 Market Dynamics and Growth

  • Positive Outlook: The sector is rated as a "Buy," with a positive outlook based on the MA50MA10 Indicator and the Stock Fear & Greed Index.
  • Growth Predictions: Tickeron forecasts a further increase of more than 4.00% in the next month, highlighting the sector's strong momentum.

💹 Industry Significance

  • Core Services Value: According to a Deloitte report, the core services of medical distributors, including efficient product distribution and inventory management, generate substantial value to the U.S. healthcare ecosystem.
  • Leading Players: Notable companies like McKesson Corporation and AmerisourceBergen Corporation are key players in this industry.

💰 Market Capitalization Insights

  • Diverse Valuations: The sector's average market cap is 17.9B, with $MCK at the high end with 62.6B and $EDAP at the lower end with 181.3M.
  • Valuation Impact: These valuations indicate the diverse scale and financial strength of companies within the sector.

📊 Price Movement Analysis

  • Monthly Growth: The sector's average monthly growth of 5.61% is indicative of its robust performance.
  • Stock Highlights: While $OMI leads with a 14.44% increase, $PDCO's decline presents a contrasting picture within the sector.

🔊 Volume Trends

  • Volume Growth: An average weekly volume growth of 338.68% signals active market participation and investor interest.
  • Volume Indicators: Significant volume increases in stocks like $EDAP highlight specific companies capturing investor attention.

📉 Fundamental Analysis Ratings

  • Comprehensive Ratings: The sector's overall strong ratings in Valuation, P/E Growth, and SMR suggest healthy fundamentals.
  • Investor Considerations: These ratings provide insights into the sector's financial health and potential growth.

🔍 Sector Outlook

The Medical Distributors sector, led by companies like $CAH, $MCK, $HSIC, $OMI, and $PDCO, is experiencing significant growth. This trend is fueled by the increasing demand for medical products and efficient distribution services. As the healthcare landscape evolves, this sector remains a vital component of the global health ecosystem, offering promising opportunities for traders and investors.

The Medical Distributors sector's recent performance is a testament to its critical role in healthcare and its potential for growth. With diverse market capitalizations, dynamic price movements, and strong fundamentals, this sector offers a range of opportunities for informed investment decisions. Keep an eye on these developments for strategic trading insights in this essential industry. 🌟📈

Related Ticker: FOCL, CAH, MCK, COR, HSIC, OMI, PDCO, ZYXI

Aroon Indicator for FOCL shows an upward move is likely

FOCL's Aroon Indicator triggered a bullish signal on August 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 188 similar instances where the Aroon Indicator showed a similar pattern. In of the 188 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FOCL's RSI Oscillator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 55 cases where FOCL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in of 248 cases, the price rose further within the following month. The odds of a continued upward trend are .

FOCL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for FOCL turned negative on August 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

FOCL moved below its 50-day moving average on August 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for FOCL crossed bearishly below the 50-day moving average on August 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FOCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.212) is normal, around the industry mean (20.130). P/E Ratio (0.000) is within average values for comparable stocks, (43.555). FOCL's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.395). FOCL's Dividend Yield (0.000) is considerably lower than the industry average of (0.007). P/S Ratio (2.037) is also within normal values, averaging (6.223).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

Notable companies

The most notable companies in this group are McKesson Corp (NYSE:MCK).

Industry description

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

Market Cap

The average market capitalization across the Medical Distributors Industry is 19.28B. The market cap for tickers in the group ranges from 557.05K to 104.16B. MCK holds the highest valuation in this group at 104.16B. The lowest valued company is CNBI at 557.05K.

High and low price notable news

The average weekly price growth across all stocks in the Medical Distributors Industry was -0%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was -28%. FOCL experienced the highest price growth at 4%, while HKPD experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Medical Distributors Industry was -15%. For the same stocks of the Industry, the average monthly volume growth was -12% and the average quarterly volume growth was 220%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 55
Price Growth Rating: 61
SMR Rating: 89
Profit Risk Rating: 77
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
FOCL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of minimally invasive medical devices for urological diseases

Industry MedicalDistributors

Profile
Details
Industry
Biotechnology
Address
N/A
Phone
N/A
Employees
N/A
Web
N/A
Interact to see
Advertisement
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
EDSA (Edesa Biotech) is up more than 21% today largely on speculative trading in a very illiquid penny stock with no clear, company‑specific news catalyst, likely driven by technical factors, retail flows, and short‑term trading rather than fundamentals.
Q4 2025 revenue came in strong at about 214–215 million, up mid‑30s percent year over year and a few percent above estimates, but GAAP EPS was only 0.08 versus expectations around 0.31, a roughly 70–75% miss and down from 0.13 a year earlier.
Estée Lauder Companies Inc. (EL) has rebounded with ~12% YTD gains and 50%+ one-year returns, supported by margin improvements and strong skincare/fragrance demand despite broader prestige beauty challenges.
Coherent Corp (COHR) has surged 200%+ over the past year and 35% YTD, fueled by AI datacenter demand and strong Q2 fiscal 2026 results (17% YoY revenue growth). QUALCOMM Incorporated (QCOM) trades at a reasonable PE of 29x with 15% YTD gains, but memory shortages have constrained handset sales, partially offset by growth in data center chips. Taiwan Semiconductor Manufacturing Company Limited (TSM) leads with 96% one-year returns and 28% YTD, supported by record AI chip sales and projected 53.8% quarterly earnings growth.
RIME (Algorhythm Holdings Inc.) is up more than 24% today mainly because its SemiCab unit landed a high‑profile pilot with Coca‑Cola’s largest bottling partner in India, reinforcing bullish sentiment around its AI freight platform and sparking aggressive retail and momentum buying in a thinly traded penny stock.
GDDY (GoDaddy) is down more than 17% today because its 2026 revenue outlook and near‑term sales guidance came in below Wall Street expectations, reinforcing worries about slowing growth and intense AI‑driven competition even though Q4 2025 headline results were solid.
For the first half of fiscal 2026, organic net sales and adjusted EPS both declined about 3% year over year and missed analyst expectations, with U.S. spirits and Chinese white spirits particularly weak. Management cut full‑year 2026 guidance again, now expecting organic sales to fall 2–3% and organic operating profit to be flat to up only low single digits, versus a prior outlook of flat to slightly down sales and low‑ to mid‑single‑digit profit growth.
DRVN (Driven Brands) is down more than 36% today because the company disclosed serious errors in its past financial statements, is delaying its Q4 2025 earnings release, and will have to restate results for the last two fiscal years, which shattered investor confidence and raised concerns about leverage and profitability.
Q4 2025 revenue was strong at about 257–258 million (up roughly 16% year over year and above forecasts), but adjusted EPS was 0.30 versus about 0.31–0.32 expected, and EBITDA of about 101–102 million was a touch below consensus.